Narrative review examines abscopal effect potential in non-small cell lung cancer multimodality therapies
When One Tumor Shrinks, Others Can Too—Here’s How
This narrative review evaluates the abscopal effect in non-small cell lung cancer patients treated with radiotherapy, lung ablation, or immu…
A new review explains how treating one lung tumor can help shrink tumors elsewhere in the body, offering a new way to think about cancer tre…
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 show improved risk discrimination for immune-toxicity-associated systemic injury
New Tool Predicts Immune Drug Organ Damage
This translational multicohort study evaluated patients receiving immune checkpoint inhibitors in United States electronic health record dat…
A new system helps doctors predict which patients might suffer dangerous organ injury from powerful cancer drugs, giving them time to act so…
Review: PD1/PDL1 spatial interactions predict pembrolizumab response in metastatic urothelial carcinoma
New Scan Shows Exactly Which Immune Cells Fight Cancer
This review discusses a proof-of-concept study examining PD1/PDL1 spatial interactions in tumor samples from patients with metastatic urothe…
This new method lets doctors see exactly which immune cells are actually fighting the tumor, not just hanging out nearby.
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis
15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
A retrospective cohort analysis of 2,401 patients with metastatic renal cell carcinoma receiving first-line immune-based combination therapy…
Real-world kidney cancer patients experience fewer severe side effects from immunotherapy than clinical trials suggest, offering relief to t…
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…
Network meta-analysis of immunotherapy for persistent, recurrent, or metastatic cervical cancer
Do newer immunotherapies help people with advanced cervical cancer live longer?
This systematic review and network meta-analysis of phase III trials synthesized evidence on first-line immunotherapy regimens for persisten…
Newer immunotherapy combinations help people with advanced cervical cancer live longer and shrink tumors better than standard chemotherapy a…
Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
New Hope for Bladder Cancer Patients Who Can’t Tolerate Standard Chemo
This phase 3 randomized controlled trial enrolled 344 patients with muscle-invasive bladder cancer ineligible for cisplatin-based chemothera…
A new two-drug treatment more than doubles the odds of staying cancer-free for bladder cancer patients who can't handle standard chemo.
Narrative review explores CSF1R inhibitor potential in pediatric medulloblastoma precision immunotherapy
The Hidden Reason Children's Brain Tumors Respond So Differently to Treatment
This narrative review examines the role of CSF1R inhibitors as precision immunotherapy for pediatric medulloblastoma subtypes.
Each subtype of children's brain tumors has a unique immune fingerprint, meaning matching treatment to that specific environment could drama…
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.